MRX34 therapy led to an increase in active tumor-infiltrating immune cells (CD8+) and a decrease in exhausted tumor-infiltrating immune cells (CD8+PD1+) that indicate an active immune response and reduced tumor tolerance [29]. This evidence concerns the gene CD8A and neoplasm.